La Retatrutida rava zita guru Kana tichikurukura nezveramangwana remishonga yekuderedza uremu uye kurapa chirwere cheshuga cherudzi rwechipiri, zvakakosha kuziva kuti kunyangwe ichiri muchikamu chekutsvagisa uye isingawanikwe muma pharmacy, data rekutanga kubva kukiriniki kuyedzwa kwaunza mufaro mukuru pakati pevanachiremba nevarwere.
Kusiyana nemamwe madhiragi akadai semaglutide (Ozempic, Wegovy) kana tirzepatide (Mounjaro, Zepbound), the Retatrutide inoshanda panguva imwe chete pamahomoni matatu akakosha ane chekuita nechido, shuga yeropa, uye metabolismIzvi zvinoisa danho mberi mukubudirira, asi zvinomutsawo mibvunzo pamusoro pekuchengetedzwa kwenguva refu uye njodzi dzekurasikirwa nekureruka nekukurumidza.
Chii chinonzi retatrutide uye chii chinoita kuti ive yakasiyana?
Iyo retatrutide, inonziwo LY-3437943 kana "triple G"Iyo peptide parizvino iri kuvandudzwa nekambani yemishonga Eli Lilly. Inoitwa kuburikidza nevhiki nevhiki subcutaneous jekiseni uye inoitirwa kurapwa kwekufuta, kuwandisa necomorbidities, uye mhando 2 chirwere cheshuga.
Iyo inozivikanwa seatatu agonist nekuti Iyo panguva imwe chete inomutsa GLP-1, GIP, uye glucagon receptorsAya mahormone matatu emudumbu akabatanidzwa zvakanyanya mukudzora havi, mashandisirwo esimba, uye kudzora glucose. Mimwe mishonga yemazuva ano inongoshanda pane imwe chete kana maviri eiyi receptors.
Mukuita, izvi zvinoreva kuti retatrutide inogona kuderedza nzara, kunonoka kubuda mudumbu, uye kukurumidza kushandisa simbaMune mamwe mazwi, inokubatsira kuti udye zvishoma, unzwe wakaguta kwenguva yakareba, uye kupisa macalorie akawanda, kunyangwe pakuzorora.
Muzvinyorwa zvakaburitswa kusvika zvino, kunyanya mujenari New England Journal of MedicineMhedzisiro yacho yave ichishamisa zvekuti nyanzvi dzakati wandei dzakatsanangura iyi katatu agonist mishonga sezvinobvira "Kumhanya kumba" mukurapa kufutisatichienzanisa kuita kwayo nekutamba kwakanaka mubaseball.
Retatrutide inoshanda sei mumuviri?
Iyo nzira yekuita retatrutide yakavakirwa pa kutevedzera maitiro matatu echisikigo mahomoni izvo zvinogadzirwa muura uye pancreas. Imwe neimwe inopa chidimbu chakasiyana kune iyo puzzle yekudzora uremu uye metabolism.
GLP-1 receptor agonism
Kunge semaglutide nemamwe madhiragi mumhuri yayo, retatrutide inoshanda pane glucagon-like peptide-1 (GLP-1) receptorNenzira iyi:
- Inowedzera insulin kusunungurwa apo mazinga eglucose anokwira mushure mekudya.
- Inoderedza kugadzirwa kweglucagon, hormone inokwidza shuga muropa.
- Inononoka kubuda mudumbusaka chikafu chinogara mudumbu kwenguva refu.
- Kunowedzera kunzwa kuguta pamwero weuropi, zvichibatsira kudya zvishoma pasina kunetseka kwakanyanya.
Zvese izvi zvinosimudzira zvirinani glycemic control uye a kungoerekana kuderera mukudya kwekoriori, chimwe chinhu chinokosha pakuchengetedza uremu.
GIP receptor agonism
Chinangwa chechipiri chekudzorerazve ndeye glucose-inotsamira insulinotropic peptide (GIP) receptorIyi incretin hormone:
- Inowedzera insulin mhinduro apo mazinga eglucose akakwirira.
- Inobata basa mumafuta metabolismkunatsiridza mashandisiro anoita muviri nekuchengetedza lipids.
- Zvinoita sezvinobatsira a simba rakanyanya kushanda yatova yakanaka metabolic profil.
Iyo GLP-1 + GIP musanganiswa yakatoratidza kuti ine simba kwazvo netirzepatide uye retatrutide. Inowedzerawo imwe nzira yechitatu yekuwedzera.
Glucagon receptor agonism
Iyo mbiru yechitatu yeiyo retatrutide mhedzisiro ndeye activation ye glucagon receptorKunyangwe glucagon inowanzobatanidzwa nekusimudza shuga yeropa, ine rimwe basa rinonakidza padanho re metabolic:
- Inowedzera basal metabolic rateNdiko kuti, macalorie akapiswa pakuzorora.
- Inosimudzira mafuta oxidation, zvichikurudzira muviri kushandisa mafuta anoiswa sechitubu chesimba.
- Inogona kubatsira kune a kuderedza mafuta echiropa uye visceral, iyo inonyanya kunetsa kune hutano hwemoyo.
Nekubatanidza mhedzisiro paGLP-1, GIP, uye glucagon, nzira yakazara kwazvo inowanikwa: kuderera kwekudya, kunonoka kugaya, kutungamira zvakanaka kweglucose, uye kuwedzera kushandiswa kwesimba.
Clinical miedzo yemhedzisiro: kuonda uye hutano hwemetabolism
Uchapupu huripo hunobva kunyanya kubva Phase 2 kiriniki miedzo muvakuru vane kufutisa kana kuwandisaane chirwere cheshuga kana kuti asina. Kunyange zvazvo zvidzidzo zveChikamu 3 zvisati zvapera, data yenguva pfupi inomanikidzira.
Kurasikirwa kwehuremu kune vanhu vakuru vasina chirwere cheshuga
Mune imwe yezvinyorwa zvinonyanya kutaurwa, zvakaburitswa mu New England Journal of Medicine uye colloquially inozivikanwa se "Jastreboff study", yaisanganisira vanhu vakuru vane BMI ≥ 30 (obesity) kana pakati pe27 ne30 ine uremu-hune chokuita nekomorbidities.
Vatori vechikamu vakagamuchira retatrutide kana placebo kuburikidza nevhiki nevhiki subcutaneous jekiseni kwemavhiki e48, ane maitiro akasiyana-siyana (1 mg, 4 mg, 8 mg uye 12 mg) uye nzira dzinofambira mberi dzetitration yekuvandudza kushivirira.
ari migumisiro Migumisiro yekurasikirwa nehuremu yaishamisa:
- Pamasvondo makumi maviri nemana, kurasikirwa kwehuremu kwaive kunenge 7,2% ne1 mg12,9% ne 4 mg, 17,3% ne 8 mg uye 17,5% ne 12 mg, zvichienderana chete ~ 1,6% ne placebo.
- Pamasvondo makumi mana nemasere, kurasikirwa kweavhareji kwakasvika pakunenge 8,7% ne1 mg17,1% ine 4 mg, 22,8% ine 8 mg uye 24,2% ne12 mg, zvichienzaniswa ne2,1% muboka re placebo.
Kunze kweavhareji, zvinotevera zvinoorora zviyero yevanhu vanozadzisa zvinangwa zvekurasikirwa nehuremu:
- Ne 4 mg, inenge iyo 92% yakarasikirwa ne5% yehuremu hwavo, 75% yakasvika ≥10% uye 60% yakasvika ≥15%.
- ne8 mg, a 100% yakawana ≥5%, 91% ≥10% uye 75% ≥15%.
- Ne 12 mg, chaizvoizvo varwere vese vakapfuura 5% uye ruzhinji zvakare zvikumbaridzo zve10 ne15%.
Zvimwe zvidzidzo zvakashuma kurasikirwa nehuremu kusvika pakati pe22 ne31% yehuremu hwemuviri mukati memwedzi 8-9, tichisvika pamigumisiro yokuvhiyiwa kwebariatric, chimwe chinhu icho kutozosvikira munguva pfupi yapfuura chairatidzika kuva chisingafungiki nemishonga.
Kuvandudzwa kwemetabolism uye hepatic mamaki
Kupfuura nhamba pachiyero, retatrutide yakaratidza zvakakosha metabolic mabhenefiti mune zvidzidzo zvakaitwa:
- Triglyceride kuderedza kusvika kune imwe chete 40%.
- Kuderera kweapoC-III protein yakatenderedza a 38%, iyo inobatanidzwa nechepasi yemwoyo ngozi.
- Kuderera kwakanyanya mumafuta echiropa, ine zvingangoitika zvakanaka pamafuta echiropa chirwere.
- Kuvandudzwa kwa insulin sensitivity uye mukudzora glycemic mune vanhu vane matambudziko apfuura.
- Kuderera kwakakosha mu kudzvinyirira kweropa muvazhinji vatori vechikamu.
Pakazara, chimiro che retatrutide chinonongedza kwete chete kune uremu-kurasikirwa nemishonga, asi kune a chishandiso chine simba chekuvandudza hutano hwese metabolic, chimwe chinhu chakakosha muvarwere vane kufutisa uye dzakawanda njodzi zvinhu.
Kuenzanisa ne semaglutide uye tirzepatide
Imwe yemibvunzo yakajairika ndeyekuti ndizvo here Retatrutide inopfuura semaglutide uye tirzepatide, mishonga miviri yakatochinja kurapa kufutisa mumakore achangopfuura.
Semaglutide (Ozempic, Wegovy nevamwe)
Semaglutide is a Exclusive agonist yeGLP-1 receptor Yakatenderwa kubva 2017 yerudzi rwechipiri chirwere cheshuga uye, zvichizodaro, chekusingaperi huremu kudzora muvanhu vane kufutisa kana kuwandisa vane comorbidities.
Muzvidzidzo zvekurasikirwa nehuremu kune vanhu vakuru vasina chirwere cheshuga, yakakwira-dose semaglutide (senge iyo inoshandiswa muWegovy) inowana paavhareji. kuderera kwehuremu hunosvika 15% yehuremu hwemuviri mushure memavhiki makumi matanhatu nemasereIzvi zvabuda zvakatoratidza shanduko kana zvichienzaniswa nemishonga yapfuura.
Panyaya yekuchengeteka, mhedzisiro yayo yakawanda yakashata ndeye kuda kurutsa, kurutsa, manyoka uye, mune dzimwe nguva, pancreatitis kana gastroparesisMamiriro asingawanzoitika akatsanangurwa zvakare, akadai seasiri-arteritic anterior ischemic optic neuropathy, pamusoro peiyo mamwe masangano, akadai seAEMPS, akapa yambiro yekudzivirira.
Tirzepatide (Mounjaro, Zepbound)
Tirzepatide a mbiri agonist yeGLP-1 uye GIP, zvakare yakagadzirwa naEli Lilly. Yakatanga kutenderwa yerudzi rwechipiri chirwere cheshuga uye gare gare chekutonga uremu (semuenzaniso seZepbound).
Muzvidzidzo zvakakura senge chirongwa cheSURPASS uye mimwe miedzo yakanangana nekufutisa, tirzepatide yakaratidza. kuderera kwehuremu kusvika ku20% mumavhiki makumi manomwe nemaviri, kudarika kushanda kwe semaglutide mune dzakawanda ongororo.
Yayo yakaipa mhedzisiro mbiri yakafanana neyevamwe GLP-1 agonists: Gastrointestinal kusagadzikana, kunyanya kuda kurutsa, kurutsa, uye manyoka, kakawanda sezvo dose inowedzera (kusvika ku 15 mg), iyo inowedzerawo chikamu chekusiya.
Ko retatrutide inomira papi maererano navo?
Yekutanga data inoratidza kuti retatrutide, ine yayo katatu agonism GLP-1 + GIP + glucagonInopa hukuru hukuru hwekurasikirwa uremu pakati pevatatu:
- Retatrutida: avhareji kurasikirwa kwe 22-24% mukati memavhiki makumi mana nemasere muChikamu 2, nevamwe varwere vanopfuura 30%.
- Tirzepatide: kumativi a 20% mumavhiki makumi matanhatu nemasere.
- Semaglutide: pedyo ne 15% mumavhiki makumi matanhatu nemasere.
Mukuwedzera, retatrutida inoita seinobatsira mamwe mabhenefiti e metabolic (triglycerides, apoC-III, mafuta echiropa, BP) inonyanya kukosha kune vanhu vane metabolic syndrome uye high cardiovascular risk.
Zvisinei, zvinofanira kurangarirwa kuti kuenzanisa kunonyanya kukosha mazano (zvidzidzo zvakasiyana, vanhu vakasiyana) uye izvo Iko hakuna musoro-kune-musoro-kune-musoro miedzo. pakati peaya mamorekuru kuita mhedziso dzechokwadi.
Migumisiro uye kuchengeteka profile
Sezvimwe nemamwe ma incretin agonists, retatrutide haina mhedzisiro yakaipa. Mashoko akanaka ndeokuti, kusvika ikozvino, iyo global security profile MuChikamu 2, inoonekwa seyakafanana neyemishonga inotozivikanwa semaglutide kana tirzepatide.
Kazhinji kacho maitiro
Matambudziko anowanzo dzoka mumiedzo ndeemhando digestivokunyanya kana kuwedzera dose:
- Kushungurudzikanekusimba kwakasiyana, kunyanya pakutanga kana mushure mekuwedzera kwedosi.
- Kuputika, kakawanda nemishonga yakawanda.
- manyoka kana, zvakapesana zvakanyanya, kupukunyuka.
- Kusagadzikana kwemudumbu, kuzvimba, uye kusanzwa kuda kudya.
Kazhinji, izvi zvinokonzeresa zvinowanzova zvinyoro kana zvine mwero uye zvishoma nezvishoma nekufamba kwenguvakunyanya kana uchishandisa zvishoma nezvishoma titration, kutanga nemishonga yakaderera (semuenzaniso, 2 mg pane 4 mg).
Zvimwe zvakaonekwa mhedzisiro
Dzakatsanangurwawo mimwe mhedzisiro:
- Kuwedzera kwe cardiac frecuencyiyo inoratidzika kunge yakanyanya kutenderera vhiki 24 uye yobva yaderera.
- Kuneta kana kunzwa kuneta kwevamwe vatori vechikamu.
- Kukwidziridzwa kwenguva pfupi kwe chiropa enzymes, pasina ikozvino kushandura mumatambudziko makuru echiropa maererano nedata iripo.
- Mune zvimwe zvidzidzo, kuchinja kwemoyo conduction zvisina kuiswa sezviitiko zvakakomba, izvo zvinoramba zvichiongororwa.
Nekuda kwekuti mushonga une simba wekukonzeresa uremu nekukurumidza, zviitiko zveakaipa zvabudawo. matombo eitsvo, kushaya simba, kurasikirwa kwemasumbu uye matambudziko mukudzikamisa uremu kana chinangwa chave chasvikwa, kunyanya muvanhu vanorasikirwa nekurema zvakanyanya.
Vamwe varwere mumiedzo vasvika nokuzvidira kuderedza dose, kunonoka kana kusvetuka jekiseni kumisa kuonda, nepo vamwe vakaedza kutsiva neakanyanya-makoriori ekudya kuti vadzivise kuwedzera uremu, izvo zvinoratidza kuti mhedzisiro yacho inogona kuve yakadii.
Njodzi dzekukurumidza kurasikirwa nekurema zvakanyanya
Iko kushanda kunoshamisa kwe retatrutide kune yakaderera: Kurasikirwa uremu nekukurumidza hakusi kukuvadza nguva dzoseNyanzvi dzakawanda dzakatanga kunyevera nezvenjodzi dzinogona kuitika dzine chekuita nekuonda kwakanyanya munguva pfupi.
Pakati pe matambudziko Zvinotevera zvinoratidzwa:
- Kurasikirwa kwakanyanya kwemhasuru, nekunzwa kwekushaya simba uye njodzi huru yekudonha kana kukuvara.
- Wedzera mukati bone fragility uye njodzi inogona kuwedzera yekutyoka kana chikafu uye kudzidziswa kwesimba zvikasatarisirwa.
- Biliary matambudziko, kusanganisira nduru, inotozivikanwa semamwe madhiragi ekurasikirwa.
- Ngozi ye chirwatata uye zvimwe zvakashata zvinokonzerwa nemasabolism mumamiriro ezvinhu ehuremu hwakanyanya kuchinja.
- Kupera simba kwesimba rekudzivirira zvirwere apo kudya kunovaka muviri kusina kukwana.
- Matambudziko ekudya kana kuipa kwehukama nechikafu muvanhu vanotambura.
Chimwe chinonetsa ndechekuti chii chinoitika apo kurapwa kunomiswa pakupera kwemiedzo kana zvimwe zvikonzero. Sezvakaonekwa ne semaglutide uye tirzepatide, chikamu chikuru chehuremu hwakarasika chinogona kuwanikwa zvakare kana pasina hupenyu hwakadzama uye hunoramba huchichinja, izvo zvinogona kuwedzera kuvhiringidzika uye kukanganisa hutano hwepfungwa.
Vanamazvikokota vakati wandei vakasimbirira kuti iyo hutano system, sezvayakarongeka parizvino, Haina kugadzirira kupa zvakanyanya kutevera. Kune varwere vese vanoshandisa mishonga iyi ine simba kunze kwekuyedzwa kwekuyedzwa: pane kushomeka kwevanovaka muviri, nyanzvi dzepfungwa, uye zvirongwa zvakarongwa zvekutsigira munhu kuburikidza nekurwiswa kwekuchinja kwemuviri nepfungwa.
Zvakanakira uye zvisingakwanisi retatrutide pakurasikirwa uremu
Kana humbowo hwese hwehumbowo hukaongororwa, retatrutida inopa chiedza chakajeka uye mimvuri icho chinhu chekuchengeta mupfungwa usati wazvifungidzira semashiripiti wand.
Kubatsira kwakanyanya
- Kuwedzera uremu munguva shoma kupfuura mamwe madhiragi emazuva ano, anosvika nhamba dziri pedyo nekuvhiyiwa kwebariatric.
- Yakafara kwazvo metabolic kunatsiridza: glucose, triglycerides, apoC-III, BP, mafuta echiropa, nezvimwewo.
- Humbowo hwekutanga hwe kuchengetedzwa zviri nani kwemhasuru mune mamwe mapoka evarwere vachienzaniswa nezvingatarisirwa zvichipiwa ukuru hwekureruka.
- Kusununguka kwekushandisa: subcutaneous jekiseni kamwe pavhiki.
Kuganhurirwa uye kumirira matambudziko
- Haisati yatenderwa neFDA kana masangano eEurope; inoramba iri mushonga wekuongorora.
- Kushaikwa kwedata renguva refu pamusoro pekuchengetedza, kuchengetedza uremu uye mhedzisiro panhengo dzakanangwa.
- Unoda sanganisa nekudya, kurovedza muviri, uye tsigiro yepfungwa.; pachayo haigadzirise zvikonzero zvinokonzera kufutisa.
- Musiyano wega wega mukushivirira uye kupindura, nevamwe vanhu vanonyanya kufunga nezvekudya kana zvemoyo.
- Zvakanaka kurema kukuru kana kurapwa kuchimiswa pasina chirongwa chakasimba chekuchengetedza.
Retatrutide ichawanikwa riini?
Parizvino, retatrutide inowanikwa mukati advanced clinical research phaseIyo Phase 2 miedzo yakatopedzwa uye yakaongororwa, uye Eli Lilly akazivisa chinangwa chayo chekuenderera mberi neChikamu 3 zvidzidzo kusimbisa kushanda uye kuchengetedzeka mumapoka makuru evarwere.
Zvinoenderana nefungidziro dzakasiyana siyana uye zvirevo munhau dzakanyanya, maitiro ekutonga anotarisirwa kukwanisa kupedzwa pakati pa2026 na2027kunze kwekunge iyo Phase 3 mhedzisiro inogutsa uye hapana zvisingatarisirwe zviratidzo zvekuchengetedza zvinoonekwa.
Kusvika panguva iyoyo, retatrutide inogona kushandiswa chete mukati kudzora miedzo yekirinikiAya ndiwo maitiro ekiriniki anodzorwa umo varwere vanosaina chibvumirano chavanoziva uye vanotariswa zvakanyanya. Kunze kwechirevo ichi, kushandiswa kwayo kwese kwekurapa hakusi kuwanikwa kana pamutemo.
Retatrutide mune zvimwe zvidzidzo: kurwadziwa kwemajoini uye comorbidities
Pamusoro pemiyedzo yakatarisana nekufutisa uye chirwere cheshuga, kune zvidzidzo zvinoenderera mberi zvinoongorora retatrutide mu. varwere vane kufutisa kana kuwandisa uye mabvi osteoarthritisChinangwa munyaya iyi chakapetwa kaviri: kutarisa kana mushonga wacho unoderedza marwadzo emajoini uye, panguva imwe chete, unobatsira pakurasikirwa.
Mumiedzo iyi, vatori vechikamu vanogamuchira svondo rega rega retatrutide kana placebo ne subcutaneous jekiseni uye inoteverwa kwenguva yakareba (semuenzaniso, kusvika munaNovember 2025 mune imwe yemaprotocol). Kufambira mberi kwemarwadzo kunoongororwa uchishandisa osteoarthritis-specific scales, pamwe chete nekuchinja kwehuremu hwemuviri uye mamwe mararamiro ehutano.
Rudzi urwu rwekudzidza rwunovavarira kujekesa kuti kusanganiswa kwe yakaderedzwa mechanical mutoro nekuda kwekureruka uye zvinogoneka zvakananga chiito pane kuzvimba Izvi zvinogona kushandura mukiriniki yakakosha kuvandudzwa mukurwadziwa uye kushanda muvanhu vane osteoarthritis.
Retatrutida inopesana nemamwe mapeptide ekupisa mafuta uye kuderedza dumbu
Nekusimuka kweGLP-1 agonists uye musanganiswa wakafanana, zvinonzwisisika kuti vanhu vazhinji vari kushamisika kuti chii "Best peptide" yekurasikirwa nedumbu mafutaIyo iripo data inoratidza kuti retatrutide inonyanya kusimba mukuderedza mafuta ese uye, kunyanya, visceral mafuta.
Muwongororo iyo boka pamwe chete gumi nemiedzo uye zviuru zvevatori vechikamu, zvakafungidzirwa kuti retatrutide inogona kuwana avhareji yekurasikirwa nehuremu hwe22% mukati memwedzi gumi neimweichienzaniswa neyakakomberedza 14% ine semaglutide pane imwe nguva yakareba. Musiyano uyu unoratidza hukuru hwakajeka, kunyangwe nguva dzose huri pasi pekusimbiswa nezvidzidzo zvakanangana nekuenzanisa.
Chiito pane glucagon receptor inoonekwa seimwe yemakiyi eku kuwedzera kushandiswa kwesimba uye kukurudzira mafuta oxidationiyo inogona kutsanangura chikamu chekukanganisa kwayo pamafuta emudumbu uye zvimiro zvakaita semafuta echiropa.
Retatrutide dosage yekurasikirwa nehuremu mumiedzo
Sezvo mushonga uchiri kugadzirwa, the Retatrutide dosing mirayiridzo iri kunatswa mumakiriniki ekuedzwaZvirongwa zvakasiyana zvetitration uye madosi evhiki akaedzwa kuti awane chiyero chepamusoro pakati pekushanda uye kushivirira.
Zvimwe zvidzidzo zvakaongorora mazinga edosi anobva kubva inenge 2,5 mg kusvika 15 mg pavhiki, nepo mune mamwe Phase 2 miedzo 1, 4, 8 uye 12 mg yakashandiswa. Muzhinji, hukama hwekupindura-dose hunoonekwa: iyo yakakwira dhigirii, iyo yakakura kurasikirwa uremu, asiwo iyo yakawanda gastrointestinal mhedzisiro.
Tsvagiridzo inoratidza kuti huwandu hwe 5 kusvika 10 mg vhiki nevhiki Inogona kupa kuwirirana kwakanaka pakati pekubudirira uye kushivirira kune vanhu vazhinji, nguva dzose nekuwedzera zvishoma nezvishoma kubva pamadhora mashoma kuderedza kusagadzikana kwekudya.
Zvakakosha kusimbisa kuti zvose izvi chikamu che optimization yemuenzaniso mumamiriro ekuedzwa, uye kuti muyero wakazobvumidzwa nemasangano unogona kusiyana zvichienderana nemhedzisiro yeChikamu 3 uye sarudzo dzekutonga.
Maonero enyanzvi uye nharo dzetsika
Kubuda kweiyo retatrutide uye mamwe ari kuwedzera ane simba GLP-1 analogues aunza zvakanyanya. gakava pakati penyanzvi mukufutisa, endocrinology uye hutano hweveruzhinjiKune rimwe divi, ivo vanomiririra mukana usina kumbobvira waitika wekurapa dambudziko iro kusvika nguva pfupi yadarika rakangoita kuvhiyiwa kwebariatric senge yakakwira-impact sarudzo.
Kune rumwe rutivi, kune kunetseka kuri kuwedzera pamusoro "mujaho wemaoko" pakati pemakambani makuru emishonga saEli Lilly naNovo Nordisk yekugadzira mamorekuru anowana mapeji epamusoro ekurasikirwa nehuremu munguva shoma, inosundwa muchikamu netarisiro yemusika uye kudzvanywa kwevanodyara mari.
Dzimwe nyanzvi dzinoti kufurirwa nehuwandu hwehuwandu hwehuremu hwakarasika Izvi zvinogona kushandura kutarisisa kubva pane izvo zvakakosha chaizvo: kuumbwa kwemuviri (tsandanyama-kune-mafuta reshiyo), hutano hwese metabolic, uye kugara zvakanaka kwepfungwa. Vatsoropodzi vakaratidzawo kuti FDA nevamwe vatongi vanoisa mberi ukuru hwekurasikirwa kwehuremu sechikonzero chekutanga mumiedzo, pane kutarisa zvakanyanya pahutano hwehupenyu, hurema, kana kugadzikana kwenguva refu.
Zvichipa zvisingadiwe mhedzisiro yakabatana nekuomarara uremu, iyo indasitiri pachayo yatanga gadzirisa hurukuro yake, achitaura zvishoma nezve "kuonda" uye zvimwe nezvehutano hweseZvisinei, chokwadi ndechekuti kukwezva kwekutengeserana kwezviverengero zvekurasikirwa nehuremu kunoramba kune simba.
Kubva pane zvatinoziva kusvika ikozvino, retatrutide iri kubuda seimwe ye Mishonga yakawanda inovimbisa kurapa kufutisa uye chirwere cheshugaNehuremu husina kumboitika hunobudirira uye yakafara metabolic mabhenefiti, chigadzirwa ichi chinopa imwe ine simba. Nekudaro, simba rayo rinoda kushandiswa zvine hungwaru, kutarisisa kwakasimba kwehunyanzvi, uye nzira yakazara inodarika chiyero, kubatanidza chikafu, maekisesaizi, uye tsigiro yepfungwa kudzivirira kuwira mumusungo wekurasikirwa nehuremu chero mutengo uye kuregeredza hutano hwese.